Kaposi's sarcoma risk redefines development of OX40/OX40L inhibitors rocatinlimab and amlitelimab for atopic dermatitis.
Is Kaposi's sarcoma the end of the OX40/OX40L axis in atopic dermatitis?
Abstract
Kaposi's sarcoma cases linked to rocatinlimab and amlitelimab necessitate a refined development strategy for OX40/OX40L axis modulation in atopic dermatitis.